Ionis Pharma’s Olezarsen Receives FDA Fast Track Designation for Familial Chylomicronemia Syndrome (FCS) Treatment
Ionis pharmaceuticals receives fast-track designation from U.S. Food and drug administration (FDA) for olezarsen in Familial chylomicronemia syndrome (FCS) treatment. Olezarsen (formerly IONIS-APOCIII ...
Jubilant Therapeutics’ JBI-778 Granted Orphan Drug Designation by US FDA for Glioblastoma Multiforme Treatment
Jubilant Therapeutics, a clinical-stage biopharmaceutical company, has announced that JBI-778, an oral PRMT5 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration ...
XORTX Therapeutics Submits Orphan Drug Designation Request for XRx-008 Program to FDA for ADPKD Treatment
XORTX Therapeutics Inc., a late-stage clinical pharma company focused on developing novel therapies to treat progressive kidney disease, has submitted an Orphan Drug Designation request to the U.S. Fo ...